Class Action Blight: The Sour Side Of Apple Stem Cell Anti-Aging Boom
This article was originally published in The Rose Sheet
Plant stem cell actives such as Mibelle Biochemistry's PhytoCellTec Malus Domestica were marquee ingredients for skin-care brands in the flourishing US anti-aging market years back. But what once was fruitful has turned rotten with regulatory crackdowns in recent years and class actions that continue to weigh on product manufacturers.
You may also be interested in...
The estimated $700,000 settlement puts to rest allegations that the luxury skin-care firm deceived consumers with claims about its PhytoCellTec ingredient’s ability to slow the aging process. G.M. Collin, another PhytoCellTec Malus Domestica user, also appears to have reached a deal with plaintiffs in litigation challenging its anti-aging claims.
The online universe is abuzz with complaints about 2016, with some ready to dub the year “worst ever.” It certainly was a rough one for anti-aging skin-care marketers, and while FDA’s warning letter activity has declined of late, consumer lawsuits continue to file challenging companies’ clock-reversing promises.
Class actions against cosmetics firms show no sign of slowing down, and FTC’s pending settlement with L’Oreal for gene-related anti-aging claims likely will spur further litigation in the sector, Edwards Wildman Palmer partner Ronie Schmelz says.